Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06528392 · ClinicalTrials.gov registry record · Phase 2

Efgartigimod for Stiff Person Syndrome (ESPS)

A Phase 2 study, sponsored by University of South Florida.

Not yet
Registry status
Phase 2
Development phase
10
Enrollment target

NCT06528392: Clinical Trial Phase 2 study, sponsored by University of South Florida.

NCT06528392 is a Phase 2 study that has not yet begun recruiting, run by University of South Florida. The registered enrollment target is 10 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06528392, a Phase 2 study, has not yet begun recruiting, sponsored by University of South Florida.

NOT YET RECRUITING
Registry status
Phase 2
Development phase
10 participants
Enrollment target

Study Summary

The goal of this clinical trial is to examine the proportion of patients with stiff person syndrome with no worsening in stiffness and/or spasms while on efgartigimod-hyaluronidase (EFD) when compared to their current treatment. The main questions it aims to answer are: * proportion of patients with stiff person syndrome with no worsening in DSI and HSS scores * whether there are changes in laboratory values, vital signs, electrocardiogram, or depression, and suicide risk during the trial, as well as the incidence of any adverse events. Participants will come to the clinic up to 18 times and have up to 5 phone call visits during the course of the trial. During these visits a variety of measures will be collected, including blood samples, neurological and physical exams, patient reported outcomes on stiffness, spasms, depression, and suicide risk.

Primary Outcome

DSI is a validated indicator or stiffness. Scores range from 0 to 6 and reflect the extent of stiffness. One point is given for stiffness in each of the following areas: lower trunk, upper trunk, legs, arms, face and abdomen.

Interventions

  • BIOLOGICAL Efgartigimod

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2025-04-01
Est. Completion 2027-12-31
Phase Phase 2
University of South Florida

252 total trials

What is known before NCT06528392 opens enrollment

NCT06528392 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% lower).

The record links to 0 conditions, and to 1 intervention - of which Efgartigimod is the first listed.

NCT06528392 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT06528392 about?

NCT06528392 is a clinical study titled "Efgartigimod for Stiff Person Syndrome (ESPS)". The goal of this clinical trial is to examine the proportion of patients with stiff person syndrome with no worsening in stiffness and/or spasms while on efgartigimod-hyaluronidase (EFD) when compared to their current treatment. The main questions it aims to answer are: * proportion of patients wit...

What is the current status of trial NCT06528392?

This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2025-04-01. Estimated completion is 2027-12-31.

What interventions are being tested in trial NCT06528392?

The interventions under investigation include: Efgartigimod (BIOLOGICAL).

Who is sponsoring clinical trial NCT06528392?

This trial is sponsored by University of South Florida, which has 252 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT06528392's enrollment target sits among peer trials

10 1968th of 2000 higher than 12 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00623389 · 10 participants · NA

    Evaluation of an Advanced Lower Extremity Neuroprostheses

  • NCT01241864 · 10 participants · Phase 2

    Islet Transplantation in Type 1 Diabetic Kidney Allograft

  • NCT01293214 · 10 participants · NA

    Vascularized Composite Allotransplantation for Multiple Extremity Amputations

  • NCT01474148 · 10 participants · NA

    A Neuroprosthesis for Seated Posture and Balance

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06528392, the US trial registry maintained by the National Library of Medicine. NCT06528392 (small enrollment · none site footprint · not yet recruiting) retrieved and formatted by PlainTrial, see methodology.